AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02958709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose: RIF, INH, PZA, EMB
Description: high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
Study NCT02958709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose: RIF, INH, PZA, LEVO
Description: high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
Study NCT02958709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care: RIF, INH, PZA, EMB
Description: standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
Study NCT04111731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon pulmonary vein isolation
Description: Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
Study NCT04111731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency pulmonary vein isolation
Description: Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
Study NCT04111731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeat electrophysiological study
Description: All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
Study NCT04111731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial posterior wall isolation
Description: The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
Study NCT01743157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochemo + bevacizumab then ipilimumab
Description: Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, \& 4)
Study NCT05703308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Menstrual Blood Stem Cells
Description: The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia
Study NCT02946762 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test and treat
Description: All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
Study NCT00605709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: API 31510 Topical Cream
Description: Topical treatments to lesion twice daily of randomized treatments.
Study NCT00605709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: API 31510 Topical Cream
Description: Topical treatments to lesion twice daily of randomized treatments.
Study NCT00605709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: API 31510 Topical Cream
Description: Topical treatments to lesion twice daily of randomized treatments.
Study NCT04013425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ice Cream Cone Technique
Description: Guided bone regeneration
Study NCT03155048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral estrogen replacement therapy
Description: oral estradiol group for endometrial preparation
Study NCT03155048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol transdermal patch
Description: transdermal estradiol group for endometrial preparation
Study NCT03178500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: stair-step clomiphene adminstration
Study NCT06114251 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of postoperative recurrence of liver cancer
Description: HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.
Study NCT02518581 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Doubly labelled water method
Description: DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
Study NCT00414466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraspinal Gabapentin
Description: Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
Study NCT00414466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraspinal Gabapentin
Description: Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
Study NCT02101346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed High Fat Diet
Description: Healthy, Round 1
Study NCT02101346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated fat diet
Description: Healthy, Round 1 Healthy, Round 2
Study NCT02101346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat diet
Description: Healthy, Round 1
Study NCT02101346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat diet
Description: Healthy, Round 1
Study NCT02101346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Triolein 13C
Description: Healthy, Round 2
Study NCT02101346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat
Description: Healthy, Round 1
Study NCT03720262 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mesh reinforcement
Description: Reinforcement of the abdominal wall with Ultrapro Advanced.
Study NCT03720262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No reinforcement
Description: Suturing the abdominal wall without mesh reinforcement
Study NCT01078025 — intervention group
Intervention type: PROCEDURE
Intervention: Smear test vaginally, intraabdominally
Description: Pre- and intraoperative smear tests of the vagina and douglas are performed.
Study NCT00826930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
Study NCT01706536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: EP-101 Placebo AM + EP-101 Placebo PM
Study NCT01706536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 12.5 mcg
Description: EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
Study NCT01706536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 25 mcg
Description: EP-101 25 mcg AM + EP-101 25 mcg PM
Study NCT01706536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 50 mcg
Description: EP-101 50 mcg AM + EP-101 50 mcg PM
Study NCT01706536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 100 mcg
Description: EP-101 100 mcg AM + EP-101 100 mcg PM
Study NCT03681509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole
Study NCT03681509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose placebo capsule
Study NCT00775177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate 100mg tablets
Description: Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
Study NCT00775177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline monohydrate 100mg tablets
Description: Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
Study NCT01524653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg po od
Study NCT01524653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 mg po od
Study NCT05390437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention with Ready to use theraputic food (RUTF) and prebiotic GOS (galacto oligosaccharides) in combination
Description: 4gm of prebiotic GOS ( Galactooligosaccharides) and Ready to use theraputic food (RUTF) as per WHO standard on daily basis for 60 Days
Study NCT05390437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready to use theraputic food (RUTF) and Starch (placebo)
Description: Ready to use therapeutic food (RUTF) as per WHO standard and (Starch Placebo) soluble in water and mix in food on daily basis for 60 Days
Study NCT06059326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10 mg
Description: Tablet, HSK7653 10 mg Q2W, 12 weeks
Study NCT06059326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 25 mg
Description: Tablet, HSK7653 25 mg Q2W, 12 weeks
Study NCT06059326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 50 mg
Description: Tablet, HSK7653 50 mg Q2W, 12 weeks
Study NCT06059326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 0 mg Q2W, 12 weeks
Study NCT03207581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professional Coaching
Description: Professional, individualized coaching
Study NCT03207581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Coaching
Description: Professional, individualized coaching
Study NCT00595608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterimar Spray
Description: Post-op nasal spray, three times a day
Study NCT00595608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic homemade nasal saline spray (salt and water)
Description: post op nasal saline spray in syringe, three times a day
Study NCT01239121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIE-Enhanced Medication Reconciliation
Description: Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
Study NCT01239121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HIE-Enhanced Medication Reconciliation
Description: Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
Study NCT01239121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medication Reconciliation without HIE
Description: Medication reconciliation implemented by a pharmacist without regional health information exchange
Study NCT01677078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronavigation system
Description: Neuronavigation
Study NCT01677078 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard localisation method
Description: Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
Study NCT00758186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency endoscopic colonic stenting
Description: Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
Study NCT00758186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency surgery
Description: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
Study NCT03048500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03048500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study NCT03048500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02602925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose decrease
Description: Treatment strategy change: dose decrease based on PASI and DLQI
Study NCT02602925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study NCT03528200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Contrast
Description: The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed.
Study NCT02977026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CYD
Study NCT02977026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AHC
Study NCT01246830 — intervention group
Intervention type: RADIATION
Intervention: Panoramic radiograph, Cephalometric radiograph
Description: 2D images that are used for orthodontic treatment planning
Study NCT01246830 — intervention group
Intervention type: RADIATION
Intervention: Cone-beam computed tomography (CBCT)
Description: CBCT data will be used in 3D cephalometric analysis softwares
Study NCT00144625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4weeks
Study NCT04619810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nurse intervention program
Description: Implementation of a specific care program for patients receiving immunotherapy for lung cancer
Study NCT02625454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Description: 1000 mg Acetaminophen q 6 hours, given intravenously
Study NCT02625454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Acetaminophen
Description: 1000 mg Acetaminophen q 6 hours given orally
Study NCT00048126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
Study NCT00048126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg po bid
Study NCT02305823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Study NCT02305823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Study NCT02305823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Study NCT01288352 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: early standardised rhythm control
Description: Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~1. Optimal antiarrhythmic drug therapy~2. Catheter ablation with the aim of pulmonary vein isolation (PVI),~3. Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences.
Study NCT03283254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practical Resources for Effective Postpartum Parenting (PREPP)
Description: A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting). PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.' The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.
Study NCT03283254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual (ETAU)
Description: Psychoeducation, Clinical Assessment, Potential Referral: Participants receive usual care along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum. At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate.
Study NCT02445300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® Ag Surgical dressing (study group)
Description: The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
Study NCT02445300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sofra-Tulle® dressing (control group)
Description: The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
Study NCT01636570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Sugar Pill
Description: Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
Study NCT01636570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol)
Description: 10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
Study NCT02637232 — intervention group
Intervention type: OTHER
Intervention: Mirvaso® / Onreltea TM
Study NCT00377871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biological heart valve prosthesis
Description: Two heart valve designs
Study NCT03900624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticus
Study NCT01340430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab